Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 9/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | G6PD | P11413 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2357860 | 0.99 | SLC6A5 (0.55) | SLC6A5CRHBPCRHR2MEN1KMT2A | |
| SCHEMBL2284163 | 0.97 | SLC6A5 (0.52) | SLC6A5CRHBPCRHR2MEN1KMT2A | |
| SCHEMBL2284700 | 0.95 | SLC6A5 (0.52) | SLC6A5CRHBPCRHR2MEN1KMT2A | |
| SCHEMBL4249716 | 0.88 | SLC6A5 (0.58) | SLC6A5CRHBPCRHR2MEN1KMT2A | |
| SCHEMBL4245123 | 0.88 | SLC6A5 (0.58) | SLC6A5CRHBPCRHR2MEN1KMT2A | |
| SCHEMBL2286302 | 0.85 | SLC6A5 (0.56) | SLC6A5CRHBPCRHR2MEN1KMT2A | |
| SCHEMBL4603996 | 0.80 | TP53 (0.55) | SLC6A5CRHBPCRHR2MEN1KMT2A | |
| SCHEMBL4244977 | 0.78 | TDP1 (0.61) | SLC6A5MEN1KMT2ACYP2B6LMNA | |
| SCHEMBL4246097 | 0.78 | SLC6A5 (0.47) | SLC6A5CRHBPCRHR2MEN1KMT2A | |
| SCHEMBL4244663 | 0.77 | TP53 (0.58) | SLC6A5TP53TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003699-B2 | Amide compound and use thereof for controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-23 | — | — | US | disclosed |
| US-8003699-B2 | Amide compound and use thereof for controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-23 | — | — | US | disclosed |
| US-8003699-B2 | Amide compound and use thereof for controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20100105647-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-04-29 | — | — | US | disclosed |
| US-20100105647-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-04-29 | — | — | US | disclosed |
| US-20100105647-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-04-29 | — | — | US | disclosed |
| EP-2151432-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | Sumitomo Chemical Company, Limited (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105647-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | CYC1, CBR3, CBR1 | SLC6A5 4673/4885CRHBP 2904/4885CRHR2 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.